Return on Equity (ROE)
since 2005
Calculation
Celgene Corp., ROE, long-term trends, calculation
| ROE | = | 100 | × | Net income (loss) attributable to Celgene1 | ÷ | Stockholders’ equity1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2018 | 65.67% | = | 100 | × | 4,046) | ÷ | 6,161) |
| Dec 31, 2017 | 42.48% | = | 100 | × | 2,940) | ÷ | 6,921) |
| Dec 31, 2016 | 30.29% | = | 100 | × | 1,999) | ÷ | 6,599) |
| Dec 31, 2015 | 27.07% | = | 100 | × | 1,602) | ÷ | 5,919) |
| Dec 31, 2014 | 30.65% | = | 100 | × | 2,000) | ÷ | 6,525) |
| Dec 31, 2013 | 25.94% | = | 100 | × | 1,450) | ÷ | 5,590) |
| Dec 31, 2012 | 25.57% | = | 100 | × | 1,456) | ÷ | 5,694) |
| Dec 31, 2011 | 23.91% | = | 100 | × | 1,318) | ÷ | 5,513) |
| Dec 31, 2010 | 14.71% | = | 100 | × | 881) | ÷ | 5,984) |
| Dec 31, 2009 | 17.68% | = | 100 | × | 777) | ÷ | 4,395) |
| Dec 31, 2008 | -43.93% | = | 100 | × | (1,534) | ÷ | 3,491) |
| Dec 31, 2007 | 7.96% | = | 100 | × | 226) | ÷ | 2,844) |
| Dec 31, 2006 | 3.49% | = | 100 | × | 69) | ÷ | 1,976) |
| Dec 31, 2005 | 10.01% | = | 100 | × | 64) | ÷ | 636) |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
The net income attributable to the company exhibits significant fluctuations over the analyzed period. Starting with a modest profit in 2005 and 2006, there is a notable surge in 2007. However, 2008 marks an exceptional downturn, with a substantial net loss recorded, indicating a challenging year likely due to extraordinary factors or operational difficulties. Following this loss, the net income recovers sharply in 2009 and demonstrates a consistent upward trajectory through 2018, culminating in a peak that is substantially higher than the earlier years. This pattern reflects a strong recovery and growth phase after the setback in 2008.
Stockholders' equity shows a generally increasing trend from 2005 to 2010, nearly tripling during this timeframe, which suggests capital growth and reinvestment in the company. After reaching its highest point in 2010, equity fluctuates somewhat but remains relatively stable, with minor increases and decreases, ending 2018 at a level slightly below the peak achieved earlier. This stability after initial growth may indicate a mature phase of capital structure management.
The return on equity (ROE) percentage further illustrates the company's financial performance and profitability relative to shareholder investment. After a low point in 2006, ROE improves markedly in 2007, then dramatically falls into negative territory in 2008 due to the aforementioned net loss. From 2009 onward, ROE consistently improves year-over-year, reflecting increased profitability efficiency. By 2018, the ROE reaches an exceptionally high level, more than doubling from a decade earlier, suggesting significant value creation for shareholders and effective utilization of equity capital during this period.
- Net Income Trends
- Modulo profits early on with a sharp decline in 2008 followed by a sustained recovery and progressive growth through 2018.
- Stockholders’ Equity Trends
- Strong growth until 2010 with relative stability and minor fluctuations thereafter until 2018.
- Return on Equity Trends
- Recovery from negative values post-2008 with steep upward trends indicating improved profitability and efficient equity use, culminating in peak performance by 2018.
Comparison to Competitors
Celgene Corp., ROE, long-term trends, comparison to competitors
| Celgene Corp. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2018 | 65.67% | — | 67.15% | 35.07% | 9.40% | 32.88% | 25.51% | 25.60% | 23.30% | 17.59% | 27.91% | 10.65% | 47.28% |
| Dec 31, 2017 | 42.48% | 104.16% | 7.84% | 8.58% | 9.45% | -1.76% | 22.64% | 2.16% | 6.97% | 29.47% | 19.51% | 8.76% | 12.99% |
| Dec 31, 2016 | 30.29% | 128.41% | 25.85% | 27.55% | 11.10% | 19.54% | 71.48% | 23.49% | 9.78% | 12.12% | 20.13% | 9.39% | -9.69% |
| Dec 31, 2015 | 27.07% | 130.39% | 24.71% | 10.97% | 14.17% | 16.53% | 97.70% | 21.66% | 9.94% | 10.75% | 17.40% | 9.25% | -59.19% |
| Dec 31, 2014 | 30.65% | 101.84% | 20.01% | 13.49% | 11.11% | 15.55% | 78.45% | 23.40% | 24.50% | 12.81% | 13.69% | 9.22% | -68.70% |
| Dec 31, 2013 | 25.94% | 91.90% | 23.00% | 16.91% | 12.04% | 26.57% | 27.05% | 18.68% | 8.85% | 28.83% | 21.74% | 7.55% | -32.81% |
| Dec 31, 2012 | 25.57% | 156.85% | 22.80% | 14.39% | 12.58% | 27.69% | 27.84% | 16.74% | 11.63% | 17.93% | 60.24% | 7.62% | -10.71% |
| Dec 31, 2011 | 23.91% | — | 19.35% | 23.25% | 12.85% | 32.11% | 41.60% | 16.94% | 11.50% | 12.18% | -45.65% | 8.84% | 3.76% |
| Dec 31, 2010 | 14.71% | — | 19.32% | 19.74% | 13.08% | 40.82% | 49.48% | 23.57% | 1.58% | 9.40% | -19.79% | 6.74% | -149.74% |
| Dec 31, 2009 | 17.68% | — | 20.32% | 71.49% | 9.90% | 45.45% | 41.40% | 24.25% | 21.85% | 9.59% | -17.10% | 5.51% | -58.57% |
| Dec 31, 2008 | -43.93% | — | 20.58% | 42.86% | 13.43% | -30.76% | 48.43% | 30.46% | 41.63% | 14.08% | -19.75% | 6.66% | -192.51% |
| Dec 31, 2007 | 7.96% | — | 17.72% | 20.50% | 15.08% | 21.61% | 46.69% | 24.41% | 18.01% | 12.53% | -22.94% | 5.25% | -144.23% |
| Dec 31, 2006 | 3.49% | — | 15.56% | 15.86% | 16.89% | 24.25% | -65.54% | 28.11% | 25.25% | 27.10% | -47.24% | 1.21% | -40.89% |
| Dec 31, 2005 | 10.01% | — | 17.96% | 26.77% | 17.67% | 18.34% | 26.88% | 27.49% | 25.85% | 12.32% | -83.72% | 7.99% | -85.05% |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Celgene Corp., ROE, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Celgene Corp. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2018 | 65.67% | 26.29% |
| Dec 31, 2017 | 42.48% | 14.59% |
| Dec 31, 2016 | 30.29% | 22.19% |
| Dec 31, 2015 | 27.07% | 21.44% |
| Dec 31, 2014 | 30.65% | 20.91% |
| Dec 31, 2013 | 25.94% | 20.33% |
| Dec 31, 2012 | 25.57% | 18.27% |
| Dec 31, 2011 | 23.91% | 15.52% |
| Dec 31, 2010 | 14.71% | 13.99% |
| Dec 31, 2009 | 17.68% | 20.34% |
| Dec 31, 2008 | -43.93% | 21.31% |
| Dec 31, 2007 | 7.96% | 17.07% |
| Dec 31, 2006 | 3.49% | 21.86% |
| Dec 31, 2005 | 10.01% | 19.08% |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Celgene Corp., ROE, long-term trends, comparison to industry (health care)
| Celgene Corp. | Health Care | |
|---|---|---|
| Dec 31, 2018 | 65.67% | 18.65% |
| Dec 31, 2017 | 42.48% | 14.05% |
| Dec 31, 2016 | 30.29% | 18.22% |
| Dec 31, 2015 | 27.07% | 18.18% |
| Dec 31, 2014 | 30.65% | 18.58% |
| Dec 31, 2013 | 25.94% | 18.25% |
| Dec 31, 2012 | 25.57% | 17.51% |
| Dec 31, 2011 | 23.91% | 15.27% |
| Dec 31, 2010 | 14.71% | 14.32% |
| Dec 31, 2009 | 17.68% | 19.27% |
| Dec 31, 2008 | -43.93% | 19.00% |
| Dec 31, 2007 | 7.96% | 16.88% |
| Dec 31, 2006 | 3.49% | 20.24% |
| Dec 31, 2005 | 10.01% | 18.16% |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).